View Item 

Show simple item record

Blood Substitutes in Cardiac Surgery

dc.contributor.authorWahr, Joyce A.en_US
dc.contributor.authorTremper, Kevin K.en_US
dc.date.accessioned2010-04-14T13:47:07Z
dc.date.available2010-04-14T13:47:07Z
dc.date.issued1998en_US
dc.identifier.citationWahr, Joyce; Tremper, Kevin (1998). "Blood Substitutes in Cardiac Surgery." Seminars in Cardiothoracic and Vascular Anesthesia 2(4): 272-282. <http://hdl.handle.net/2027.42/68576>en_US
dc.identifier.issn1089-2532en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/68576
dc.description.abstractA safe, inexpensive, noninfectious substitute for red blood cells has long been sought. Despite tremendous advances in blood banking, the logistics of collecting, transporting, and storing human red blood cells contin ues to create infection and shortage problems. The two basic types of blood substitutes currently under devel opment are hemoglobin based and fluorocarbon based. Although they each transport oxygen differently, the basic advantages and limitations are the same. Blood substitute advantages include the unique capacity for room temperature storage, noninfectivity, adequate supply, and low toxicity. Restrictions include limited dosing in the acute period, limited intravascular half-life and, for the fluorocarbons, a requirement for a high PaO2. In addition, there remain questions about the relationship of nitric oxide metabolism to hypertension in hemoglobin solutions. Early clinical and laboratory trials have shown that both types of solutions are effective oxygen-delivery agents, with acceptable side- effect profiles. Clinical trials are currently underway to determine the safety and efficacy of these solutions in patients undergoing cardiopulmonary bypass.en_US
dc.format.extent3108 bytes
dc.format.extent972185 bytes
dc.format.mimetypetext/plain
dc.format.mimetypeapplication/pdf
dc.publisherSage Publicationsen_US
dc.titleBlood Substitutes in Cardiac Surgeryen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialitiesen_US
dc.subject.hlbsecondlevelSurgery and Anesthesiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Department of Anesthesiology, Ann Arbor, MIen_US
dc.contributor.affiliationumUniversity of Michigan, Department of Anesthesiology, Ann Arbor, MIen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/68576/2/10.1177_108925329800200403.pdf
dc.identifier.doi10.1177/108925329800200403en_US
dc.identifier.sourceSeminars in Cardiothoracic and Vascular Anesthesiaen_US
dc.identifier.citedreferenceNewman R., Podolsky D.: Bad blood. U S News World Rep (June 27):68-78,1994en_US
dc.identifier.citedreferenceNicholls MD: Transfusion: Morbidity and mortality. Anaesth Intensive Care 21:15-19, 1993en_US
dc.identifier.citedreferenceSazama K.: Report of 355 transfusion-associated deaths: 1976-1985. Transfusion 30:583-590, 1990en_US
dc.identifier.citedreferenceMyhre BA: Fatalities from blood transfusion. JAMA 244:1333-1335, 1980en_US
dc.identifier.citedreferenceBlumberg N., Triulzi DJ, Heal JM: Transfusion-induced immunomodulation and its clinical consequences. Transfus Med Rev 4:24-35, 1990en_US
dc.identifier.citedreferenceBordin JO, Blajchman MA: Immunosuppressive effects of allogeneic blood transfusions: Implications for the patient with a malignancy. Hematol Oncol Clin North Am 9:205-218,1995en_US
dc.identifier.citedreferenceLanders DF, Hill GE, Wong KC, Fox IJ: Blood transfusion-induced immunomodulation. Anesth Analg 82:187-204, 1996en_US
dc.identifier.citedreferenceCrystal GJ: Myocardial oxygen supply-demand relations during isovolemic hemodilution. Adv Pharmacol 31:285-312, 1994en_US
dc.identifier.citedreferenceSpahn DR, Smith LR, Veronee CD, et al: Acute isovolemic hemodilution and blood transfusion. Effects on regional function and metabolism in myocardium with compromised coronary blood flow. J Thorac Cardiovasc Surg 105:694-704, 1993en_US
dc.identifier.citedreferenceSpahn DR, Smith LR, Mc Rae RL, Leone BJ: Effects of acute isovolemic hemodilution and anesthesia on regional function in left ventricular myocardium with compromised coronary blood flow. Acta Anaesthesiol Scand 36:628-636, 1992en_US
dc.identifier.citedreferenceSpahn DR, Smith LR, Schell RM, et al: Importance of severity of coronary artery disease for the tolerance to normovolemic hemodilution. Comparison of single-vessel versus multivessel stenoses in a canine model. J Thorac Cardiovasc Surg 108:231-239, 1994en_US
dc.identifier.citedreferenceHerregods L., Foubert L., Moerman A., et al: Comparative study of limited intentional normovolaemic haemodilution in patients with left main coronary artery stenosis. Anaesthesia 50:950-953, 1995en_US
dc.identifier.citedreferenceJalonen J., Meretoja O., Laaksonen V., et al: Myocardial oxygen balance during hemodilution in patients undergoing coronary artery bypass grafting. Eur Surg Res 16:141-147,1984en_US
dc.identifier.citedreferenceNelson AH, Fleisher LA, Rosenbaum SH: Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 21:860-866,1993en_US
dc.identifier.citedreferenceKlein HG: Oxygen carriers and transfusion medicine. Artif Cells Blood Substit Immobil Biotechnol 22:123-135, 1994en_US
dc.identifier.citedreferenceSlanetz PJ, Lee R., Page R., et al: Hemoglobin blood substitutes in extended preoperative autologous blood donation: An experimental study. Surgery 115:246-254, 1994en_US
dc.identifier.citedreferenceAmberson WR: Blood Substitutes. Biol Rev 12:48-86, 1937en_US
dc.identifier.citedreferenceTremper KK, Levine EM, Waxman K. Clinical experience with Fluosol DA (20%) in the United States, in Tremper KK (ed): International Anesthesiology Clinics: Perfluorochemical Oxygen Transport 23:185-198, 1985en_US
dc.identifier.citedreferenceClark LC, Gollan F.: Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 152:155-156, 1966en_US
dc.identifier.citedreferenceGeyer RP, Monroe RG, Taylor K.: Survival of rats having red cells totally replaced with emulsified fluorocarbon. Fed Proc 27:384; 1968en_US
dc.identifier.citedreferenceTremper KK, Friedman AE, Levine EM: The preoperative treatment of severely anemic patients with perfluorochemical emulsion oxygen transporting fluid, Fluosol-DA. N Eng J Med 307:277-283,1982en_US
dc.identifier.citedreferenceGould SA, Rosen AL, Sehgal LR, et al: Fluosol-DA as a red-cell substitute in acute anemia. N Engl J Med 314:1653-1656,1986en_US
dc.identifier.citedreferenceMartin SM, Laks H., Drinkwater DC, et al: Perfluorochemical reperfusion yields improved myocardial recovery after global ischemia. Ann Thorac Surg 55:954-960, 1993en_US
dc.identifier.citedreferenceWall TC, Califf RM, Blankenship J., et al: Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. Circulation 90:114-120, 1994en_US
dc.identifier.citedreferenceKeipert PE, Faithfull NS, Bradley JD, et al: Enhanced oxygen delivery by perflubron emulsion during acute hemodilution. Artif Cells Blood Substit Immobil Biotechnol 22:1161-1167, 1994en_US
dc.identifier.citedreferenceWahr JA, Trouwborst A., Spence RK, et al: A pilot study of the effects of a perflubron emulsion, AF 0104, on mixed venous oxygen tension in anesthetized surgical patients. Anesth Analg 82:103-107, 1996en_US
dc.identifier.citedreferenceRabiner SF, O'Brien K., Peskin GW, Friedman LH: Further studies with stroma-free hemoglobin solution. Ann Surg 171:615-622, 1970en_US
dc.identifier.citedreferenceKlocke R.: Effect of alterations in oxygen binding to hemoglobin on oxygen delivery. Pulm Critical Care Update 6:1-7, 1990en_US
dc.identifier.citedreferenceBunn HF: The use of hemoglobin as a blood substitute. Am J Hematol 42:112-117, 1993en_US
dc.identifier.citedreferenceBunn HF: The role of hemoglobin-based blood substitutes in transfusion medicine. Transfus Clin Biol 2:433-439, 1995en_US
dc.identifier.citedreferenceLeone B.: Potential clinical applications of recombinant human haemoglobin in blood conservation. Biodrug 1997 (in press)en_US
dc.identifier.citedreferenceHughes G. Jr, Francome SF, Antal EJ, et al: Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin Med 126:444-451, 1995en_US
dc.identifier.citedreferenceLee R., Neya K., Svizzero TA, Vlahakes GJ: Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J Appl Physiol 79:236-242, 1995en_US
dc.identifier.citedreferenceHess JR, Mac Donald VW, Brinkley WW: Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol 74:1769-1778, 1993en_US
dc.identifier.citedreferenceUlatowski JA, Koehler RC, Nishikawa T., et al: Role of nitric oxide scavenging in peripheral vasoconstrictor response to beta cross-linked hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 23:263-269, 1995en_US
dc.identifier.citedreferenceHughes G. Jr, Antal EJ, Locker PK, et al: Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med 24:756-764, 1996en_US
dc.identifier.citedreferenceGulati A., Sharma AC, Burhop KE: Effect of stroma-free hemoglobin and diaspirin cross-linked hemoglobin on the regional circulation and systemic hemodynamics. Life Sci 55:827-837, 1994en_US
dc.identifier.citedreferenceWinslow RM: Vasoconstriction and the efficacy of hemoglobin-based blood substitutes. Transfus Clin Biol 1:9-14, 1994en_US
dc.identifier.citedreferenceUsuba A., Miyazawa M., Motoki R., et al: Oxygen transport capacity and hemodynamic effect of newly developed artificial blood "Neo Red Cells (NRC)." Int J Artif Organs 16:551-556, 1993en_US
dc.identifier.citedreferenceThompson A., Mc Garry AE, Valeri CR, Lieberthal W.: Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: Role of nitric oxide. J Appl Physiol 77:2348-2354, 1994en_US
dc.identifier.citedreferenceSherman IA, Dlugosz JA, Perelman V., et al: Systemic hemodynamic and hepatic microvascular responses to a 33% blood volume exchange with whole blood, stroma-free hemoglobin, and oxypolyhemoglobin solutions. Biomater Artif Cells Immobilization Biotechnol 21:537-551, 1993en_US
dc.identifier.citedreferenceTsuchida E., Komatsu T.: Synthetic hemes. Methods Enzymol 231:167-193, 685-687, 1994en_US
dc.identifier.citedreferenceRudolph AS, Cliff RO, Klipper R., et al: Circulation persistence and biodistribution of lyophilized liposome-encapsulated hemoglobin: An oxygen-carrying resuscitative fluid. Crit Care Med 22:142-150, 1994en_US
dc.identifier.citedreferenceRudolph AS: Biomaterial biotechnology using self-assembled lipid microstructures. J Cell Biochem 56:183-187, 1994en_US
dc.identifier.citedreferenceDeshpande SV, Beissinger RL: Liposome-encapsulated hemoglobin using film hydration processing to form artificial red blood cells. Biomater Artif Cells Immobil Biotechnol 21:135-145, 1993en_US
dc.identifier.citedreferenceElgebaly SA, Houser SL, el Kerm AF, et al: Evidence of cardiac inflammation after open-heart operations. Ann Thorac Surg 57:391-396, 1994en_US
dc.identifier.citedreferenceEngelman RM, Rousou JA, Flack J., et al: Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg 60:801-804, 1995en_US
dc.identifier.citedreferenceKawahito K., Kawakami M., Fujiwara T., et al: Proinflammatory cytokine levels in patients undergoing cardiopulmonary bypass. Does lung reperfusion influence the release of cytokines? ASAIO J 41:M775-M778, 1995en_US
dc.identifier.citedreferenceZhao L., Smith JR, Eyer CL: Effects of a 100% perfluorooctylbromide emulsion on ischemia/reperfusion injury following cardioplegia. Artif Cells Blood Substit Immobil Biotechnol 23:513-531, 1995en_US
dc.identifier.citedreferencePremaratne S., Harada RN, Chun P., et al: Effects of perfluorocarbon exchange transfusion on reducing myocardial infarct size in a primate model of ischemiareperfusion injury: A prospective, randomized study. Surgery 117:670-676, 1995en_US
dc.identifier.citedreferenceKloner RA, Hale S.: Cardiovascular applications of fluorocarbons in regional ischemia/reperfusion. Artif Cells Blood Substit Immobil Biotechnol 22:1069-1081, 1994en_US
dc.identifier.citedreferenceCole DJ, Schell RM, Drummond JC, Reynolds L.: Focal cerebral ischemia in rats. Effect of hypervolemic hemodilution with diaspirin cross-linked hemoglobin versus albumin on brain injury and edema. Anesthesiology 78:335-342, 1993en_US
dc.identifier.citedreferenceCole DJ, Schell RM, Drummond JC: Diaspirin cross-linked hemoglobin (DCLHb): Effect of hemodilution during focal cerebral ischemia in rats. Artif Cells Blood Substit Immobil Biotechnol 22:813-818, 1994en_US
dc.identifier.citedreferenceSpiess BD, Cochran RP: Perfluorocarbon emulsions and cardiopulmonary bypass: A technique for the future. J Cardiothorac Vasc Anesth 10:83-90, 1996en_US
dc.identifier.citedreferenceRybak ME, Renzulli LA: A liposome-based platelet substitute, the plateletsome, with hemostatic efficacy. Biomater Artif Cells Immobil Biotechnol 21:101-118, 1993en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10.1177_108925329800200403.pdf
Size:
949.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.